Novavax's RSV vaccine misses in Phase III in infants

Novavax Inc. (NASDAQ:NVAX) said its ResVax RSV vaccine missed the primary endpoint in the Phase III Prepare trial to prevent respiratory syncytial virus infection in infants via maternal immunization.

In

Read the full 298 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE